

Market Announcement

3 January 2025

Argent BioPharma Limited (ASX: RGT) – Trading Halt

Description

The securities of Argent BioPharma Limited ('RGT') will be placed in trading halt at the request of RGT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 7 January 2025 or when the announcement is released to the market.

Issued by

ASX Compliance

3 January 2025

Barbara Lim
Adviser, Listings Compliance (Perth)
ASX Limited
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

Via email: barbara.lim@asx.com.au

Request for Trading Halt

Dear Barbara,

Argent BioPharma Limited (ASX: RGT) (“Argent BioPharma” or “the Company”) hereby requests that its securities be placed in a trading halt and provides the following information in accordance with ASX Listing Rule 17.1.

1. The Company requests a trading halt immediately pending the release of an announcement concerning a capital raising (**Announcement**).
2. The trading halt is to last until the earlier of the Company releasing the Announcement or prior to commencement of trading on Tuesday, 7 January 2025.
3. We expect the trading halt will end by the Company making the announcement.
4. The Company is not aware of any reason why the trading halt should not be granted.
5. The Company is not aware of any other information to inform the market about the trading halt.

Yours faithfully,

Rowan Harland
Company Secretary

Phone

+61 8 6555 2950

Email

info@argentbiopharma.com

Address

Suite 1, 295 Rokeby Road, Subiaco, WA
6008, Australia